We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

82 hedge funds and large institutions have $310M invested in Stemline Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 18

31% more capital invested

Capital invested by funds: $236M → $310M (+$74M)

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

3% more funds holding

Funds holding: 80 → 82 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

86% less call options, than puts

Call options by funds: $296K | Put options by funds: $2.15M

Holders
82
Holders Change
+2
Holders Change %
+2.5%
% of All Funds
1.88%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
31
Reduced
18
Closed
13
Calls
$296K
Puts
$2.15M
Net Calls
-$1.85M
Net Calls Change
-$2.51M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$20.7M
2
Citadel Advisors
Citadel Advisors
Florida
+$9.12M
3
State Street
State Street
Massachusetts
+$8.21M
4
ACA
Avoro Capital Advisors
New York
+$8.17M
5
NC
Nexthera Capital
New York
+$8.16M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$5.39M
2
SFM
Sphera Funds Management
Israel
-$4.68M
3
Millennium Management
Millennium Management
New York
-$3.58M
4
CCS
Crosspoint Capital Strategies
California
-$1.03M
5
JP Morgan Chase
JP Morgan Chase
New York
-$733K
Name Holding Trade Value Shares
Change 		Change in
Stake
JGC
26
J. Goldman & Co
New York
$1.24M +$486K +31,200 +62%
Invesco
27
Invesco
Georgia
$1.22M +$1.24M +79,493 New
Lazard Asset Management
28
Lazard Asset Management
New York
$1.19M +$1.22M +78,034 New
Deutsche Bank
29
Deutsche Bank
Germany
$1.13M +$368K +23,630 +47%
Millennium Management
30
Millennium Management
New York
$919K -$3.58M -229,949 -79%
Morgan Stanley
31
Morgan Stanley
New York
$862K +$147K +9,440 +20%
Charles Schwab
32
Charles Schwab
California
$832K +$114K +7,300 +16%
UBS Group
33
UBS Group
Switzerland
$793K +$628K +40,304 +348%
VEA
34
Virtus ETF Advisers
New York
$791K +$432K +27,720 +116%
Ameriprise
35
Ameriprise
Minnesota
$743K -$38.5K -2,470 -5%
TA
36
Teachers Advisors
New York
$664K – – –
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$619K +$75.7K +4,854 +14%
CM
38
Crestline Management
Texas
$583K -$538K -34,506 -48%
ELI
39
Empire Life Investments
Ontario, Canada
$514K – – –
SCA
40
Secor Capital Advisors
New York
$485K +$494K +31,719 New
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$476K – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$399K +$45.4K +2,915 +13%
DZ Bank
43
DZ Bank
Germany
$382K +$389K +24,954 New
Citigroup
44
Citigroup
New York
$374K +$372K +23,886 +4,176%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$369K +$92K +5,900 +32%
AllianceBernstein
46
AllianceBernstein
Tennessee
$360K +$65.5K +4,200 +22%
Barclays
47
Barclays
United Kingdom
$358K +$160K +10,254 +78%
Parallax Volatility Advisers
48
Parallax Volatility Advisers
California
$337K -$88.2K -5,658 -20%
Goldman Sachs
49
Goldman Sachs
New York
$333K +$339K +21,761 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$312K +$33.9K +2,177 +12%
1
2
3 4

STML Hedge Fund Activity: Q1 2018 in Review

82 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2018, worth a combined $310M — up 31% from $236M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new STML positions and 13 closed out — a net gain of 3 holders — while 31 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $20.7M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.39M.

  • 82 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2018, up from 80 in Q4 2017.
  • Funds reported $310M of Stemline Therapeutics, Inc. stock for Q1 2018, up 31% quarter-over-quarter.
  • 16 funds opened new Stemline Therapeutics, Inc. positions in Q1 2018 and 13 closed out, a net change of +3 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q1 2018 was Fidelity Investments, an estimated $20.7M added.
  • The largest Stemline Therapeutics, Inc. seller in Q1 2018 was Baker Bros. Advisors, an estimated $5.39M sold.

Based on aggregated 13F filings for Q1 2018.